Table 2 Ciprofloxacin treatment course characteristics
| Â | Phase I | Phase II | P value |
|---|---|---|---|
Treatment regimen characteristics | Â | Â | Â |
Dosing Strength | Â | Â | 1.00 |
   200 mg IV | 6 | 6 |  |
   400 mg IV | 94 | 94 |  |
Dosing Frequency | Â | Â | 0.55 |
   Once | 17 | 22 |  |
   Once daily | 5 | 3 |  |
   Twice Daily | 78 | 75 |  |
IV to PO Conversion Rate (% by treatment course) | 27 | 23 | 0.73 |
Ciprofloxacin doses/treatment course, median (range) | 5 (1–33) | 5 (1–44) | 0.55 |
   IV, median (range) | 3 (1–33) | 4 (1–25) | 0.29 |
Inappropriate IV, mean (range) | 2.4 (0–26) | 2.0 (0–9) | 0.33 |
Inappropriate & pharmacist-preventable IV, mean (range) | 1.1 (0–24) | 0.6 (0–6) | 0.14 |
   PO, mean (range) | 1.7 (0–26) | 1.6 (0–26) | 0.83 |
Treatment course acquisition costs ($) | Â | Â | Â |
Ciprofloxacin, median (range) | 99 (17–1089) | 132 (17–825) | 0.32 |
   IV, median (range) | 99 (17–1089) | 132 (17–825) | 0.28 |
Inappropriate IV, mean (range) | 72 (0–790) | 60 (0–274) | 0.39 |
Inappropriate & pharmacist-preventable IV, mean (range) | 34 (0–729) | 20 (0–182) | 0.17 |